PSYCHOPHARMACOLOGICAL TREATMENT OF SOCIAL PHOBIA (SP)
description
Transcript of PSYCHOPHARMACOLOGICAL TREATMENT OF SOCIAL PHOBIA (SP)
PSYCHOPHARMACOLOGICAL TREATMENT OF SOCIAL PHOBIA (SP)
Professor Jiří Raboch, M.D.
Psychiatric Department
1st. Medical Faculty
Charles University Prague
TREATMENT OPTIONS
• CBT
• MONOAMINE OXIDASE INHIBITORS• BENZODIAZEPINES• BETA-BLOCKERS• SSRIs• DUAL REUPTAKE INHIBITORS• OTHER/NEWER AGENTS
RANDOMIZED CONTROLLED TRIALS
RESPONSE RATE
clinically significant reduction of symptoms
Clinical Global Impression Scale-Improvement (CGI-I) – „very much“ or „much improved“
50 % drop in the Liebowitz Social Anxiety Scale (LSAS)
MONOAMINE OXIDASE INHIBITORS
PHENELZINE - controlled studiesStudy Duration
(weeks)
N Response rate (%)
Tyrer et al., 1973
8 40
Gelernter et al., 1991
12 65 63 +
Liebowitz et al., 1992
8 74 64 +
Versiani et al., 1992
16 78 96 +
Heimberg et al., 1998
12 133 65 +
+ stat. sign. better than placebo
MOCLOBEMIDE – controlled studies
Study N Duration (weeks)
Response rate (%)
Versiani et al., 1992
78 16 81 +
Int. Mult. St., 1997
578 12 47/41 +
Noyes et al., 1997
583 12 ns
Schneier et al., 1998
77 12 ns
+ stat. sign. better than placebo
BENZODIAZEPINES – controlled studies
Study N Duration
(weeks)
Results
Gelernter et al., 1991
65 20 Alprazolam 38 %
Placebo 20 % (+)
Davidson et al., 1993
75 10 Clonazepam 78,3 %
Placebo 20 % (+)
+ stat. sign. better than placebo
BUSPIRONE – controlled studies
Study N Duration
(weeks)
Response rate (%)
van Vliet et al., 1997
30 12 ns
BETA-BLOCKERS – controlled studies
Study N Duration
(weeks)
Response rate (%)
Performance anxiety
11 controlled
studies
In 8 of them more than 50 % response
Liebowitz et al., 1992
atenolol
74 16 ns
SSRIs
FLUVOXAMINE – controlled studiesStudy N Duration
(weeks)
Response rate (%)
Van Vliet et al., 1994
30 12 46 +
Stein et al., 1999
86 12 43 +
Davidson et al., 2004 *
279 12 34 +++
Westenberg et al., 2004 *
300 12 48
+ p=0,05 +++ p=0,001* CR – controlled-release
PAROXETINE – controlled studies
Study N Duration
(weeks)
Response rate (%)
Stein et al., 1998
370 12 55 +
Allgulander et al., 1999
96 12 70 +
Baldwin et al., 1999
187 12 66 +
Lepola et al., 2004 *
370 12 57 +++
+ p=0,05 +++ p=0,001* CR – controlled-release
SERTRALINE – controlled studies
Study N Duration
(weeks)
Response rate (%)
Van Ameringen et al., 2001
203 20 53 ++
Blomhoff et al., 2001
387 24 40,2 +
Liebowitz et al., 2003
211 12 55,6 +++
++ p=0,01 +++ p=0,001
FLUOXETINE – controlled studies
Study N Duration
(weeks)
Response rate (%)
Kobak et al., 2002
60 14 ns
Clark et al., 2003
60 16 ns
Davidson et al., 2004
295 14 51 +
+ p=0,05
s-CITALOPRAM – controlled studies
Study N Duration
(weeks)
Response rate (%)
Kasper et al., 2002
181 24 54 +++
Lader et al.,2004
167 5 mg
170 20 mg
24 79 +
88+++
Davidson et al., 2004
315 8 68++
Kasper et al., 2005
358 12 54++
+ p=0,05 ++p=0,01 +++ p=0,001
WHAT DOSAGE? Study N Duration
(weeks)
Response rate (%)
Liebowitz et al., 2002
384 20 mg 12 31.4+++
paroxetine 40 mg 12 24.5+
Drop on LSAS
60 mg 12 25.2+
Lader et al.,2004
504 5 mg 24 79 +
s-citalopram 10 mg 24 76
% CGI-I 1,2 20 mg 24 88 +++
+ p=0,05 +++ p=0,001
SNRI
VENLAFAXINE ER – controlled studies
Study Duration
(weeks)
N Response rate (%)
Rickels et al., 2004 12 272 50++
Allgulander et al., 2004
12 434 69+
Liebowitz et al., 2005 12 440 58,6+++
Liebowitz et al., 2005 12 271 44+
+ p=0,05 ++ p=0,01 +++ p=0,001
WHICH IS BETTER?
• Few methodologically fair head to head comparisons
• Lader et al., 2004 20 mg s-citalopram better (p=0,01) than 20
mg paroxetine• Liebowitz et al., 2005 paroxetine
20-50 mg/d and venlafaxine ER 75-225 mg - similar effects
OTHER DRUGS
ANTIEPILEPTIC DRUGS -controlled studies
Study N Duration
(weeks)
Response rate (%)
Pande et al., 1999
Gabapentin
69 14 32 +
Pande et al., 2004
Pregabalin
600 mg
135 10 Better than placebo
p=0,024
+ stat. sign. better than placebo
ATYPICAL ANTIPSYCHOTICS
Barnet et al., 2003
Study N Duration (weeks)
Response rate (%)
Barnett et al., 2002
olanzapine
12 8 Improvement (p=0,01)
COMPARISON OF DRUG CLASSES FOR TREATMENT OF SF
Class Efficacy Tolerability
Safety Speed of onset
Depression
MAOIs ++ - - - ++
RIMAs + ++ + - +
SSRIs ++ ++ + - ++
BZDN + + + + -
Beta-bl. - ++ + + -
SNRI ++ + + - ++
Adapted from Westenberg, 2004
SP – first choice TREATMENT
• SSRIs – s-citalopram, fluvoxamine (CR), paroxetine (CR), sertraline, (fluoxetine)
• SNRI – venlafaxine ER
• COMBINATION – CBT + ANTIDEPRESSANTS – few data (sequencing)
SP – second choice TREATMENT and future alternatives
• MAOIs (phenelzine)
• Moclobemide
• Clonazepam
• Performance anxiety – beta-blockers – propranolol, atenolol
• Anticonvulsants, atypical antipsychotics
CONCLUSION
• THERE ARE NUMBER OF EMPIRICALLY VALIDATED ACUTE TREATMENTS FOR SOCIAL PHOBIA
• THE GOAL OF TREATMENT NEEDS TO BE REFOCUSED FROM ACHIEVING RESPONSE TO ACHIEVING REMISSION IN A LONGER PERSPECTIVE (CONTINUATION AND MAINTENANCE PHASES IN THE TREATMENT)
THANK YOU FOR YOUR ATTENTION!
HOW LONG?
• Stein et al., 2003• 112 patients with SAD, improved after 12
weeks treatment with sertraline CR (100 – 300 mg/day)
• 24 weeks extension phase• Subjects continued to improve compared
to placebo treated, although changes were smaller
TREATMENT PHASES acute 6 – 12 (or longer) weeks
continuation up to 1 yearmaintenance
CONTINUATION TREATMENT?
• Walker et al., 2000• 50 patients with generalized social phobia
much or very much improved after 20 weeks of treatments with sertraline (50-200 mg/day)
• Randomly assigned to sertraline or placebo for another 6 months
• Relapse rate: placebo group 36 %, sertraline group 4 % (p=0,01)
MAINTENANCE TREATMENT?
• Versiani et al., 1996
• 58 patients-responders with SF treated 2 years with moclobemide (600-750 mg/day)
• After 2 years moclobemide was withdrawn
• Relapse rate 88 %
Pharmacological treatment of SF: a meta-analysis
Drug Effect size 95 % CI
Phenelzine 1.02 0.52 – 1.52
Clonazepam 0.97 0.49 – 1.45
Gabapentin 0.78 0.29 – 1.27
Brofaromine 0.66 0.38 – 0,94
SSRIs 0.65 0.50 – 0.81
CI – confidence interval Blanco et al., 2003
PREDICTORS OF TREATMENT RESPONSE
• Alcohol abuse
• Comorbid personality disorder
• Earlier age of onset
• Higher heart rate and blood pressure
• Elevated baseline measures of anxiety and depression
TREATMENT RESISTENCE
• Switching – venlafaxine, phenelzine
• Augmentation – buspirone, pindolol, benzodiazepines (clonazepam), atypical antipsychotics (olanzapine, risperidone), tiababine
TREATMENT RESISTENCEcontrolled studies
Study N Duration Results
Clonazepam + paroxetine
Seedat and Stein, 2004
28 10 weeks 79 % resp. 43 %, p=0,06
Pindolol + paroxetine
Stein et al., 2001
14 4 weeks NS
CONTINUATION TREATMENT?
• Stein et al., 2002• … patients with SAD improved after 12
weeks treatment with paroxetine (20-50 mg/day)
• Randomly assigned to paroxetine or placebo for another 6 months
• Relapse rate: placebo group 40 %, sertraline group 14 % (p=0,0001)
REMISSION CRITERIA
• No longer satisfying diagnostic criteria
• CGI-I very much improved
• LSAS > 70 % reduction, < 30
• SDS < 5
COMPARISON OF DRUG CLASSES FOR TREATMENT OF SF
Class Efficacy Tolerability
Safety Speed of onset
Depression
MAOIs ++ - - - ++
RIMAs + ++ + - +
SSRIs ++ ++ + - ++
BZDN + + + + -
Beta-bl. - ++ + + -
SNRI ++ + + - ++
Adapted from Westenberg, 2004